- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00539305
Hormone and Information Processing Study (HIP)
Testosterone Supplementation in Men With MCI
연구 개요
상세 설명
Natural age related declines in testosterone (T) are associated with decreases in cognitive abilities independent of health status. Low T levels over time are associated with increased risk for developing Alzheimer's disease (AD). These findings suggest that men with low T levels are most at risk for age-related cognitive decline and AD and therefore most likely to benefit from T supplementation to prevent the development of AD or age-associated cognitive decline. The current study will assess cognition, mood, and cerebral spinal fluid (CSF) biomarker response to T supplementation in older men with mild cognitive impairment (MCI) and low T levels.
Participants will be randomized to either receive T treatment or a placebo for six months. Participants will come in for about five visits within the span of six months where they will complete cognitive & memory tests, fill out mood questionnaires, and have their blood drawn to monitor the medication level. A sample of blood will also be taken at one visit to test for apolipoprotein E (APOE), which is a genetic risk factor associated with AD. Participants will have the option to get a spinal tap in order to measure biological markers associated with Alzheimer's disease including beta-amyloid 1-40, 42, total-tau, and phosphorylated-tau-181-231. This will require an additional two visits.
연구 유형
등록 (실제)
단계
- 3단계
연락처 및 위치
연구 장소
-
-
Washington
-
Seattle, Washington, 미국, 98108
- VA Puget Sound Health Care Systems
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Male 60-90 years of age
- Diagnosis of mild cognitive impairment (MCI)
- Low testosterone level
- Primary language is English
- Availability of an informant who knows the participant well enough to answer questions
- Stable medications for the previous 3 months
- Normal complete blood count (CBC), and no clinically significant blood chemistry
- American Urological Association (AUA) symptom score less than or equal to 19
- Body Mass Index (BMI) less than 33 and stable weight in the previous year
Exclusion Criteria:
- Prior history of prostate cancer or prostate specific antigen level greater than 4.0ng/ml
- Peripheral or vascular disease
- Significant history of alcohol abuse, current alcohol abuse (more than 2 drinks per day), or other substance abuse
- History of severe head injury (with loss of consciousness greater than 30 minutes)
- Significant neurological illness, such as Parkinson's disease, seizure disorder, multiple sclerosis, major stoke
- Smokes cigarettes
- Major psychiatric illness, such as schizophrenia or bipolar disorder
Prohibited Medications:
- Anti-convulsants
- Anti-psychotics
- Sedating antihistamines
- Sedative/hypnotics
- Benzodiazepines
- Hormone or testosterone regimens
- Gonadotropin-releasing hormone (GNRH) antagonists
- Flutamide
- Anti-depressants and/or anti-cholinesterase inhibitors, but acceptable if on stable dose for 3 months or more
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
위약 비교기: 2
|
applied topically daily for six months
|
|
실험적: Study drug; testosterone transdermal gel
Dose will be adjusted as needed to maintain a target total T level of 500-900 ng/dl
|
50-100mg applied topically daily for six months
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Behavioral & Mood Measure: Profile of Mood States (POMS)
기간: Baseline, 3 and 6 months
|
Values represent self evaluation of vigor-activity.
The scale compares t-scores of participants to published norms (range 0-100), and higher scores indicate elevated emotion in subscale.
Higher t-scores in vigor-activity subscale are considered favorable.
Month 3 and Month 6 values display change from baseline.
|
Baseline, 3 and 6 months
|
|
Cognitive Changes Measured by Neuropsychological Tests: Rey Auditory Verbal Learning Test
기간: Baseline, 3 and 6 months
|
Values represent total score in Long Delay Word List Recall.
Higher score indicates higher level of functioning (range 0-15).
Month 3 and Month 6 indicate change from baseline.
|
Baseline, 3 and 6 months
|
|
Geriatric Depression Scale (GDS)
기간: Baseline, Month 3, Month 6
|
Values represent self evaluation of depression (range 0-30).
Higher scores indicate a more depressed mood.
Month 3 and Month 6 indicate change from baseline.
|
Baseline, Month 3, Month 6
|
|
Short-Form Health Survey (SF-36)
기간: Baseline, Month 3, Month 6
|
Self assessment of Physical Functioning in Health Survey.
Higher scores indicate a higher level of functioning (range 0-100).
Month 3 and 6 values represent change from baseline in subscale.
|
Baseline, Month 3, Month 6
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Monique Cherrier, PhD, University of Washington
간행물 및 유용한 링크
일반 간행물
- Cherrier MM, Asthana S, Plymate S, Baker L, Matsumoto AM, Peskind E, Raskind MA, Brodkin K, Bremner W, Petrova A, LaTendresse S, Craft S. Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology. 2001 Jul 10;57(1):80-8. doi: 10.1212/wnl.57.1.80.
- Cherrier MM, Matsumoto AM, Amory JK, Ahmed S, Bremner W, Peskind ER, Raskind MA, Johnson M, Craft S. The role of aromatization in testosterone supplementation: effects on cognition in older men. Neurology. 2005 Jan 25;64(2):290-6. doi: 10.1212/01.WNL.0000149639.25136.CA.
- Cherrier MM, Matsumoto AM, Amory JK, Asthana S, Bremner W, Peskind ER, Raskind MA, Craft S. Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment. Neurology. 2005 Jun 28;64(12):2063-8. doi: 10.1212/01.WNL.0000165995.98986.F1.
- Cherrier MM, Matsumoto AM, Amory JK, Johnson M, Craft S, Peskind ER, Raskind MA. Characterization of verbal and spatial memory changes from moderate to supraphysiological increases in serum testosterone in healthy older men. Psychoneuroendocrinology. 2007 Jan;32(1):72-9. doi: 10.1016/j.psyneuen.2006.10.008. Epub 2006 Dec 4.
- Lu PH, Masterman DA, Mulnard R, Cotman C, Miller B, Yaffe K, Reback E, Porter V, Swerdloff R, Cummings JL. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men. Arch Neurol. 2006 Feb;63(2):177-85. doi: 10.1001/archneur.63.2.nct50002. Epub 2005 Dec 12.
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- 29975-A
- R01AG027156 (미국 NIH 보조금/계약)
- 1R01AG027156-01A2 (미국 NIH 보조금/계약)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
testosterone gel에 대한 임상 시험
-
National Taiwan University Hospital알려지지 않은
-
University Hospital Southampton NHS Foundation...Vascular Solutions LLC완전한
-
Universitat de LleidaInstitut de Recerca Biomèdica de Lleida; Hospital Universitari de Santa María (Lleida -...아직 모집하지 않음
-
Zhejiang Cancer Hospital모병
-
Rabin Medical Center알려지지 않은
-
Mentor Worldwide, LLC완전한
-
Geneve TEAM AmbulancesUniversity Hospital, Geneva; ESAMB - College of Higher Education in Ambulance Care; Ambulances...완전한
-
Seoul National University Hospital완전한